Actavis PLC (ACT.N)

ACT.N on New York Stock Exchange

263.75USD
18 Dec 2014
Price Change (% chg)

$2.85 (+1.09%)
Prev Close
$260.90
Open
$265.01
Day's High
$268.26
Day's Low
$262.22
Volume
510,768
Avg. Vol
471,410
52-wk High
$272.75
52-wk Low
$158.61

ACT.N

Chart for ACT.N

About

Actavis PLC, is a global, integrated specialty pharmaceutical company. The Company focused on developing, manufacturing and distributing generic, brand and biosimilar products. The Company produces and markets generic, branded generic, branded and over-the-counter (OTC) pharmaceutical products covering all therapeutic classes.... (more)

Overall

Beta: 0.32
Market Cap (Mil.): $69,909.87
Shares Outstanding (Mil.): 265.06
Dividend: --
Yield (%): --

Financials

  ACT.N Industry Sector
P/E (TTM): -- 36.60 37.24
EPS (TTM): -4.18 -- --
ROI: -3.50 18.95 18.21
ROE: -6.36 19.73 19.11
Search Stocks

UPDATE 1-U.S. judge says Actavis must keep selling Alzheimer drug

Dec 11 - A U.S. judge said in a preliminary injunction on Thursday that Actavis Plc must continue to sell its Alzheimer's drug after a lawsuit alleged the company was trying to limit generic competition while it launched an extended-release version of the widely used medicine.

12 Dec 2014

U.S. judge rules Actavis must continue to sell Alzheimer's drug

- A U.S. judge ruled on Thursday that Actavis Plc must continue to sell its Alzheimer's drug in a lawsuit alleging that the company was scheming to limit generic competition while it launched an extended-release version of the widely used drug.

12 Dec 2014

U.S. judge rules Actavis must continue to sell Alzheimer's drug

Dec 11 - A U.S. judge ruled on Thursday that Actavis Plc must continue to sell its Alzheimer's drug in a lawsuit alleging that the company was scheming to limit generic competition while it launched an extended-release version of the widely used drug.

12 Dec 2014

FDA panel recommends approval for Actavis' antibiotic drug

- Actavis Plc said a panel advising the United States Food and Drug Administration recommended the approval of its antibiotic to treat two infections caused by drug-resistant bacteria.

06 Dec 2014

FDA panel recommends approval for Actavis' antibiotic drug

Dec 5 - Actavis Plc said a panel advising the United States Food and Drug Administration recommended the approval of its antibiotic to treat two infections caused by drug-resistant bacteria.

06 Dec 2014

Ackman's Pershing Square still holds 26.6 million Allergan shares

BOSTON, Nov 26 - Hedge fund manager William Ackman told investors in a letter that his firm still owns 26.6 million shares in Allergan Inc. which were valued at $5.6 billion one week after the Botox maker agreed to sell itself to rival pharmaceutical company Actavis Plc.

26 Nov 2014

Actavis mulls job cuts, China expansion - Bloomberg

REUTERS - Generic drugmaker Actavis Plc is planning to cut employees and expand in China, a Bloomberg report said citing an interview by Chief Executive Officer Brent Saunders on Bloomberg Television.

25 Nov 2014

Actavis mulls job cuts, China expansion - Bloomberg

Nov 24 - Generic drugmaker Actavis Plc is planning to cut employees and expand in China, a Bloomberg report said citing an interview by Chief Executive Officer Brent Saunders on Bloomberg Television.

25 Nov 2014

Valeant slashes stake in Allergan after losing bid

- (Refiles Nov. 20 story to correct reference to previous stake)

21 Nov 2014

CORRECTED-Valeant slashes stake in Allergan after losing bid

Nov 20 - Valeant Pharmaceuticals International Inc said it cut its stake in Allergan Inc to 0.1 percent, three days after Actavis Plc trumped its offer for the Botox maker.

21 Nov 2014

Earnings vs. Estimates

Search Stocks